Ask the author session with Prof. Michel Ducreux Addressing How to Treat Patients With Advanced Hepatocellular Carcinoma
Dr. Vijayvergia, Assistant Professor of Hematology and Oncology, Assistant Chief of GI Medical Oncology, Fox Chase Cancer ASCO GI 2021: trial updates Advanced HCC: IMbrave150 Trial
Dr.Molham Khalil. Dr. Li on the Subgroup Analysis of the IMbrave150 Trial in Older Patients With HCC
An influx of treatments are emerging against hepatocellular carcinoma (HCC), a common malignancy with huge unmet needs, IMbrave150 in Unresectable HCC Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal
Depth and Duration of Response Are Associated with Survival in Dr. Kaubisch on Treatment Options for HCC
IMbrave150 analysis. Oncologist. 2025 Sep 1;30(9):oyaf269. doi: 10.1093 IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Michel Ducreux, MD, PhD, of the Gustave Roussy Institute, Villejuif, France, explores the emerging synergistic mechanisms of
Philippe Merle, MD, PhD, Croix-Rousse Hospital, Lyon, France, updates on key trials that wil be presented at this years upcoming IMbrave150: The first successful Phase III trial of a cancer TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC)
With Prof. Jean-François Dufour about this journal paper: "Efficacy and Safety of Atezolizumab plus Bevacizumab versus 7/1/2021.
Key updates from ASCO GI 2021 Namrata Vijayvergia, MD, discusses updates from the IMbrave150 trial as presented at ASCO GI 2021
A video summary of the HIMALAYA study PLSP: Tremelimumab and Durvalumab for Unresectable HCC Shahid Ahmed, PhD, MD, FRCPC, FACP, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Canada, provides
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable • Here, we report updated efficacy data for IMbrave150 with 12 mo of additional follow-up (median follow-up: 15.6 mo). Page 3. Study design. Key eligibility.
Peter R. Galle, MD, the director of the Medical Department at the University Medical Center Mainz and president-elect of the AACR 2021: Dra. Renata D'Alpino aborda a análise do estudo IMbrave150 Peter R. Galle, MD, PhD, Johannes Gutenberg University, Mainz, Germany, shares updated efficacy data from the Phase III
The IMpower150 study (NCT02366143) showed that atezolizumab in combination with bevacizumab, carboplatin, and paclitaxel Daneng Li, MD, discusses the subgroup analysis of the phase 3 IMbrave150 trial in patients with unresectable hepatocellular
Mehmet Akce, MD, an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Updated efficacy and safety data from IMbrave150: Atezolizumab The role of sorafenib in the first-line treatment of HCC as seen in the IMbrave150 trial. For more resources and information
HCC podcast series part 1: The use of IO in unresectable HCC Dr. Kim, Professor of Medicine, Moffit Cancer Center, describes the IMBRAVE 150 phase 3 study and whether the overall survival Patient-Reported Outcomes Improve with Combination Treatment for Patients With HCC
Prof Richard Finn speaks to ecancer in an online interview for the virtual AACR 2021 meeting about the updated safety and Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma Daneng Li, MD, on impressions of patient reported outcomes from the IMBRAVE 150 study
Dr. Harding on the Goal of the IMbrave150 trial in HCC IMbrave150 Trial: Combination Therapy in Advanced HCC IMpower-150: EGFR-Mutated Subset Analysis
ASCO GI: updates in KEYNOTE-177, IMbrave150 & ClarIDHy Richard Kim, MD, on the outcome on the IMBRAVE 150 study & the possibility of new treatment standard
Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS IMbrave150 showed consistent clinically meaningful treatment benefit and safety with 12 mo of additional follow-up.
IMbrave150 Phase III Trial for MHCC Andreas Kaubisch, MD, associate attending physician, Montefiore Medical Center, Albert Einstein College of Medicine, discusses Dr Katie Kelley talks to ecancer in an online interview for the ASCO virtual meeting 2020 about using durvalumab and
New Options for Overcoming Resistance to Anti-VEGF Therapy in HCC IMBrave150 Regimen: Managing Varices
2021 TASL HCC Single Topic Conference Satellite symposium - Roche Impact of IMbrave150 on theadvanced HCC treatment When compared to Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), An expert clinical review of data from the EGFR-mutated subset included in the IMpower-150 trial looking at the addition of
IMbrave150: updated overall survival data from a global An overview of the IMbrave150 phase III trial data as they relate to the management of hepatocellular carcinoma. Richard S. Finn, MD, considers whether updated results from IMbrave150 are practice-changing
Dr. Li, Assistant Clinical Professor, City of Hope, shares his impressions of the IMBRAVE 150 study particularly relating to patient Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara HIMALAYA and IMbrave-150 for Hepatocellular Carcinoma: A
The use of Immunotherapy (IO) in unresectable Hepatocellular Carcinoma (HCC) Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of immune Impact of IMbrave150 Trial: APAC Expert Review Now Published
Michael Lee, MD, of UNC Lineberger Cancer Center, Chapel Hill, NC, explains the efficacy and safety results for atezolizumab Richard S. Finn, MD, discusses the significance of the results presented on the recent IMbrave150 study in unresectable IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared
Dr. Galle on Patient-Reported Outcomes From the Phase III IMbrave150 Trial To our knowledge, IMbrave150 was the first phase 3 trial since 2007 to show a significant and clinically meaningful survival benefit with Full Podcast: Experts provide an overview of current systemic treatment options for 1st line uHCC,
Daneng Li, MD, of City of Hope National Medical Center, Duarte, CA, discusses results from older adults enrolled in IMbrave150 Dr. Kaseb, Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, on the
Atezolizumab and bevacizumab for upfront unresectable HCC IMbrave150: Updated overall survival (OS) data from a global Exploring Current and Upcoming Therapies for Hepatocellular Carcinoma
Real-world experience of Impower150 regimen for EGFR+ NSCLC Dra. Renata D'Alpino, Oncologista Clínica do Grupo Oncoclínicas e Diretora Científica do Grupo Brasileiro de Tumores
In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, and consultant medical oncologist in the
Experts provide an overview of current systemic treatment options for 1st line uHCC, discussing the role of IO and IO-based Daniel Catenacci, MD, University of Chicago, Chicago, IL, provides an overview of some of the exciting data presented at this
Jawaban Webinar 5 Years of IMbrave150 - Milestones and Future Opportunities in HCC #Dokter #nilai100 A review of the phase 3 IMbrave150 trial comparing atezolizumab-bevacizumab vs standard of care, sorafenib, as initial therapy
The IMbrave150 trial showed significantly better overall survival and progression-free survival outcomes with atezolizumab plus bevacizumab than Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150
This exploratory analysis reports efficacy and safety results in patients with baseline Barcelona Clinic Liver Cancer (BCLC) stage B disease. We met up with Dr Michel Ducreux at ESMO 2018 who provided a brief review of the current treatment landscape for Treatment of advanced HCC IMbrave - 150 trail || علاج HCC IMbrave المتقدم
An overview of the phase III IMbrave150 trial, inclusion criteria, primary/secondary end points, and practical implications. Website: IMbrave150 Phase III Design, Results, and Practical Implications Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the Phase III HIMALAYA trial which investigated
Introduction. The IMbrave150 study of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) IMbrave050: adjuvant atezolizumab with bevacizumab in high-risk HCC
Checkpoint inhibition in hepatocellular carcinoma Ghassan K. Abou-Alfa, MD, MBA, leads a discussion on the management of varices occurring in patients with metastatic IMbrave150 Trial: Frontline Treatment of Advanced HCC
Additionally, an exploratory analysis of the patients with Vp4 HCC (15%) enrolled on the IMbrave-150 trial also demonstrated improved efficacy James J. Harding, MD, regional director of Early Drug Development at Memorial Sloan Kettering Cancer Center, discusses the Combination Atezolizumab Plus Bevacizumab Improved Quality of Life in HCC
Michel Ducreux, ESMO 2018 – Exploring new treatment options for hepatocellular carcinoma Synergy of anti-androgenic agents and immune checkpoint inhibitors in HCC First-line treatment options for advanced HCC including sorafenib, lenvatinib, and atezolizumab-bevacizumab as systemic
Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study Updates from IMbrave 150 in HCC Dr. Somer on the Impact of the IMbrave150 Trial on the HCC Paradigm
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Upcoming IO combinations for advanced HCC Richard S. Finn, MD, regarding the updated IMbrave150 data from ASCO GI 2021
Patient-reported outcomes with atezolizumab plus bevacizumab HIMALAYA: Does underlying liver function impact efficacy of tremelimumab plus durvalumab for HCC? IMbrave150: updated data on atezo plus bev versus sorafenib in HCC
Study Details | NCT03434379 | A Study of Atezolizumab in Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma In this animated video article, we present the phase III HIMALAYA study, which investigated tremelimumab and durvalumab for
Impact of IMbrave150 on theadvanced HCC treatment landscape: How dose it improve patient outcomes?